Merck, Inc.
🇵🇭Philippines
Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 118
- Registration Number
- NCT00687011
Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 23
- Registration Number
- NCT00686686
Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)
Phase 3
Completed
- Conditions
- Hepatitis C, ChronicLiver Cirrhosis
- Interventions
- Biological: Peginterferon alfa-2bDrug: Ribavirin
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 102
- Registration Number
- NCT00687219
Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)
Phase 3
Terminated
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: Peginterferon alfa-2b (PegIFN-2b)
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 261
- Registration Number
- NCT00686881
A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 215
- Registration Number
- NCT00687401
A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
Phase 4
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00686595
Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)
Phase 3
Completed
- Conditions
- Coronary Heart Disease (CHD)CHD Risk-Equivalent Disease
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1623
- Registration Number
- NCT00685776
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
Phase 2
Completed
- Conditions
- Cerebral Infarction
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT00684515
Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
Phase 2
Completed
- Conditions
- Myocardial IschemiaAtherosclerosisMyocardial Infarction
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00684203
Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00684567
© Copyright 2025. All Rights Reserved by MedPath